RESUMEN
OBJECTIVE: Determine whether urine biomarkers NGAL (neutrophil gelatinase-associated lipocalin), KIM-1 (kidney injury molecule 1) and IL-18 (interleukin-18) are associated with abnormal MRI findings in neonates with hypoxic-ischemic encephalopathy (HIE) who underwent therapeutic hypothermia (TH). STUDY DESIGN: Secondary analysis of a multicenter, prospective study of neonates with HIE requiring TH. Urine biomarkers were obtained at 12 and 24 h of life (HOL). Brain MRI was scored per NICHD criteria. Association between biomarkers and MRI stage was determined. RESULTS: In 57 neonates with HIE, only IL-18 at 24 HOL was significantly increased in neonates with MRI Stage 2B or greater, compared to Stage 2A or less (mean 398.7 vs. 182.9 pg/mL, p = 0.024.) A multivariate model including IL-18 at 24 HOL and 5-min Apgar performed best, with an AUC of 0.84 (SE = 0.07, p = 0.02). CONCLUSIONS: Elevated urine IL-18 at 24 HOL was associated with more severe brain MRI abnormalities among neonates with HIE.
Asunto(s)
Lesión Renal Aguda , Biomarcadores , Encéfalo , Receptor Celular 1 del Virus de la Hepatitis A , Hipotermia Inducida , Hipoxia-Isquemia Encefálica , Interleucina-18 , Lipocalina 2 , Imagen por Resonancia Magnética , Humanos , Hipoxia-Isquemia Encefálica/orina , Hipoxia-Isquemia Encefálica/diagnóstico por imagen , Recién Nacido , Biomarcadores/orina , Masculino , Femenino , Estudios Prospectivos , Lipocalina 2/orina , Lesión Renal Aguda/orina , Lesión Renal Aguda/etiología , Interleucina-18/orina , Encéfalo/diagnóstico por imagen , Receptor Celular 1 del Virus de la Hepatitis A/análisis , Análisis MultivarianteRESUMEN
OBJECTIVES: Seizures (SZ) are one of the main complications occurring in infants undergoing therapeutic hypothermia (TH) due to perinatal asphyxia (PA) and hypoxic ischemic encephalopathy (HIE). Phenobarbital (PB) is the first-line therapeutic strategy, although data on its potential side-effects need elucidation. We investigated whether: i) PB administration in PA-HIE TH-treated infants affects S100B urine levels, and ii) S100B could be a reliable early predictor of SZ. METHODS: We performed a prospective case-control study in 88 PA-HIE TH infants, complicated (n=44) or not (n=44) by SZ requiring PB treatment. S100B urine levels were measured at 11 predetermined monitoring time-points from first void up to 96-h from birth. Standard-of-care monitoring parameters were also recorded. RESULTS: S100B significantly increased in the first 24-h independently from HIE severity in the cases who later developed SZ and requested PB treatment. ROC curve analysis showed that S100B, as SZ predictor, at a cut-off of 2.78⯵g/L achieved a sensitivity/specificity of 63 and 84â¯%, positive/negative predictive values of 83 and 64â¯%. CONCLUSIONS: The present results offer additional support to the usefulness of S100B as a trustable diagnostic tool in the clinical daily monitoring of therapeutic and pharmacological procedures in infants complicated by PA-HIE.
Asunto(s)
Asfixia Neonatal , Hipotermia Inducida , Subunidad beta de la Proteína de Unión al Calcio S100 , Convulsiones , Humanos , Subunidad beta de la Proteína de Unión al Calcio S100/orina , Convulsiones/orina , Convulsiones/diagnóstico , Convulsiones/tratamiento farmacológico , Masculino , Recién Nacido , Femenino , Estudios de Casos y Controles , Estudios Prospectivos , Asfixia Neonatal/orina , Asfixia Neonatal/terapia , Asfixia Neonatal/complicaciones , Curva ROC , Hipoxia-Isquemia Encefálica/orina , Hipoxia-Isquemia Encefálica/terapia , Hipoxia-Isquemia Encefálica/diagnóstico , Fenobarbital/uso terapéutico , Lactante , Biomarcadores/orinaRESUMEN
Objective: The purpose of the present review is to evaluate whether urine uric acid to creatinine ratio is increased in perinatal asphyxia and hypoxic-ischemic encephalopathy (HIE), as well as to assess its predictive accuracy in the disease. Methods: We used the Medline (1966-2017), Scopus (2004-2017), Clinicaltrials.gov (2008-2017), Embase (1980-2017), Cochrane Central Register of Controlled Trials CENTRAL (1999-2017), and Google Scholar (2004-2017) databases in our primary search along with the reference lists of electronically retrieved full-text papers. The hierarchical summary receiver operating characteristic (HSROC) model was used for the meta-analysis of diagnostic accuracy. Results: Fourteen studies were finally included in the present review, that investigated 1226 neonates. Urinary uric acid to creatinine ratio was significantly higher in neonates with perinatal asphyxia than in healthy controls (mean differences (MD): 1.43 95%CI [1.17, 1.69]). Specifically, the mean difference for Sarnat stage 1 was 0.70 (95%CI [0.28, 1.13]), for stage 2 1.41 (95%CI [0.99, 1.84]), and for stage 3 2.71 (95%CI [2.08, 3.35]). The estimated sensitivity for the summary point was 0.90 (95%CI (0.82-0.95)), the specificity was 0.88 (95%CI (0.73-0.95)) and the diagnostic odds ratio was calculated at 63.62 (95%CI (17.08-236.96)). Conclusions: Urinary uric acid to creatinine ratio is a rapid and an easily detected biomarker that may help physicians identify neonates at risk of developing perinatal asphyxia and HIE. However, large-scale prospective studies are still needed to determine its value in predicting mortality, as well as short- and long-term adverse neurological outcomes.
Asunto(s)
Asfixia Neonatal/diagnóstico , Creatinina/orina , Diagnóstico Prenatal/métodos , Ácido Úrico/orina , Puntaje de Apgar , Asfixia Neonatal/orina , Biomarcadores/orina , Creatinina/análisis , Femenino , Humanos , Hipoxia-Isquemia Encefálica/diagnóstico , Hipoxia-Isquemia Encefálica/orina , Recién Nacido , Embarazo , Diagnóstico Prenatal/normas , Diagnóstico Prenatal/estadística & datos numéricos , Distribución Aleatoria , Sensibilidad y Especificidad , Ácido Úrico/análisis , Urinálisis/métodos , Urinálisis/normas , Urinálisis/estadística & datos numéricosRESUMEN
Perinatal asphyxia is an event affecting around four million newborns worldwide. The 0.5 to 2 per 1000 of full term asphyxiated newborns suffer from hypoxic-ischemic encephalopathy (HIE), which is a frequent cause of death or severe disability and, as consequence, the most common birth injury claim for obstetrics, gynaecologists, and paediatricians. Perinatal asphyxia results from a compromised gas exchange that leads to hypoxemia, hypercapnia, and metabolic acidosis. In this work, we applied a metabolomics approach to investigate the metabolic profiles of urine samples collected from full term asphyxiated newborns with HIE undergoing therapeutic hypothermia (TH), with the aim of identifying a pattern of metabolites associated with HIE and to follow their modifications over time. Urine samples were collected from 10 HIE newborns at birth, during hypothermia (48 hours), at the end of the therapeutic treatment (72 hours), at 1 month of life, and compared with a matched control population of 16 healthy full term newborns. The metabolic profiles were investigated by 1H NMR spectroscopy coupled with multivariate statistical methods such as principal component analysis and orthogonal partial least square discriminant analysis. Multivariate analysis indicated significant differences between the urine samples of HIE and healthy newborns at birth. The altered metabolic patterns, mainly originated from the depletion of cellular energy and homeostasis, seem to constitute a characteristic of perinatal asphyxia. The HIE urine metabolome changes over time reflected either the effects of TH and the physiological growth of the newborns. Of interest, the urine metabolic profiles of the HIE non-surviving babies, characterized by the increased excretion of lactate, resulted significantly different from the rest of HIE population.
Asunto(s)
Hipotermia Inducida , Hipoxia-Isquemia Encefálica/terapia , Hipoxia-Isquemia Encefálica/orina , Metaboloma , Metabolómica , Espectroscopía de Protones por Resonancia Magnética , Asfixia Neonatal , Estudios de Casos y Controles , Femenino , Humanos , Hipotermia Inducida/métodos , Hipoxia-Isquemia Encefálica/mortalidad , Recién Nacido , Estudios Longitudinales , Masculino , Metabolómica/métodosRESUMEN
BACKGROUND: Lipid peroxidation mediated by reactive oxygen species is a major contributor to oxidative stress. Docosahexaenoic acid (DHA) has anti-oxidant and neuroprotective properties. Our objective was to assess how oxidative stress measured by lipid peroxidation was modified by DHA in a newborn piglet model of hypoxia-ischemia (HI). METHODS: Fifty-five piglets were randomized to (i) hypoxia, (ii) DHA, (iii) hypothermia, (iv) hypothermia+DHA or (v) sham. All groups but sham were subjected to hypoxia by breathing 8% O2. DHA was administered 210 min after end of hypoxia and the piglets were euthanized 9.5 h after end of hypoxia. Urine and blood were harvested at these two time points and analyzed for F4-neuroprostanes, F2-isoprostanes, neurofuranes and isofuranes using UPLC-MS/MS. RESULTS: F4-neuroprostanes in urine were significantly reduced (P=0.006) in groups receiving DHA. Hypoxia (median, IQR 1652 nM, 610-4557) vs. DHA (440 nM, 367-738, P=0.016) and hypothermia (median, IQR 1338 nM, 744-3085) vs. hypothermia+DHA (356 nM, 264-1180, P=0.006). The isoprostane compound 8-iso-PGF2α was significantly lower (P=0.011) in the DHA group compared to the hypoxia group. No significant differences were found between the groups in blood. CONCLUSION: DHA significantly reduces oxidative stress by measures of lipid peroxidation following HI in both normothermic and hypothermic piglets.
Asunto(s)
Ácidos Docosahexaenoicos/farmacología , Hipotermia Inducida/métodos , Hipoxia-Isquemia Encefálica/metabolismo , Estrés Oxidativo/fisiología , Animales , Animales Recién Nacidos , Modelos Animales de Enfermedad , Femenino , Hipoxia-Isquemia Encefálica/sangre , Hipoxia-Isquemia Encefálica/orina , Peroxidación de Lípido/fisiología , Fármacos Neuroprotectores/farmacología , Embarazo , Porcinos , Resultado del TratamientoRESUMEN
The initial diagnosis of neonatal hypoxic-ischemic encephalopathy is based on nervous system clinical manifestations. The use of biomarkers to monitor brain injury and evaluate neuroprotective effects allows early intervention and treatment. This study was designed to determine the short-term prognostic significance of urinary S100B calcium-binding protein (S100B) in asphyxiated newborns treated with hypothermia.An observational prospective study was conducted over a period of 5 years in 31 newborns with hypoxic-ischemic encephalopathy who received therapeutic hypothermia. The patients were divided into 2 groups: Group A (13 newborns with a normal neurological examination before discharge) and Group B (18 newborns who died during admission or had an abnormal neurologic examination before discharge). Urinary S100B was the main variable, serum S100B and neuron-specific enolase (NSE) were considered as secondary variables, and all of them were assessed on the first 3 days of life. The newborns were subsequently divided into groups with normal and abnormal electrophysiological and imaging findings.Mean urinary S100B levels were significantly higher in group B than group A on day 1 (10.58â±â14.82 vs 4.65â±â9.16âµg/L, Pâ=â.031) and day 2 (5.16â±â7.63 vs 0.88â±â2.53, Pâ=â.002). The optimal cutoff for urinary S100B on day 1 was >1.11âµg/L of (sensitivity, 100%; specificity 60%) for the prediction of neonatal death andâ<â0.66âµg/L (sensitivity 83% and specificity 70%) for the prediction of a normal neurological examination before discharge. It was not possible to calculate cutoffs with a similar accuracy for serum S100B or NSE. Urinary S100B on day 1 was higher in patients with abnormal magnetic resonance imaging findings (7.89â±â8.09 vs 4.49â±â9.14, Pâ=â.039) and abnormal positron emission tomography findings (8.60â±â9.29 vs 4.30â±â8.28, Pâ=â.038). There were no significant differences in S100B levels between patients with normal and abnormal electroencephalography results.Urinary S100B measured in the first days of life can predict neonatal death and short-term prognosis in asphyxiated newborns treated with hypothermia. The method is convenient, noninvasive, and has a higher sensitivity and specificity than measurement of serum S100B or NSE.
Asunto(s)
Hipotermia Inducida/métodos , Hipoxia-Isquemia Encefálica/orina , Subunidad beta de la Proteína de Unión al Calcio S100/orina , Biomarcadores/sangre , Biomarcadores/orina , Electroencefalografía , Femenino , Humanos , Hipoxia-Isquemia Encefálica/sangre , Hipoxia-Isquemia Encefálica/terapia , Recién Nacido , Masculino , Examen Neurológico/métodos , Muerte Perinatal/etiología , Fosfopiruvato Hidratasa/sangre , Pronóstico , Estudios Prospectivos , Subunidad beta de la Proteína de Unión al Calcio S100/sangre , Sensibilidad y EspecificidadRESUMEN
The prompt and reliable identification of infants at risk of hypoxic-ischemic encephalopathy secondary to perinatal asphyxia in the first critical hours is important for clinical decision-making and yet still remains a challenge. This work strives for the evaluation of a panel of metabolic biomarkers that have been associated with the hypoxic-ischemic insult in the perinatal period. Plasma and urine samples from a consolidated newborn piglet model of hypoxia and withdrawn before and at different time points after a hypoxic insult were analyzed and compared to a control group. Time-dependent metabolic biomarker profiles were studied and observed patterns were similar to those of lactate levels, which are currently considered the gold standard for assessing hypoxia. Class prediction performance could be improved by the use of a combination of the whole panel of determined metabolites in plasma as compared to lactate values. Using a multivariate model including lactate together with the studied metabolic biomarkers allowed to improve the prediction performance of duration of hypoxia time, which correlates with the degree of brain damage. The present study evidences the usefulness of choline and related metabolites for improving the early assessment of the severity of the hypoxic insult.
Asunto(s)
Asfixia Neonatal/fisiopatología , Biomarcadores , Hipoxia-Isquemia Encefálica/fisiopatología , Ácido Láctico/metabolismo , Animales , Animales Recién Nacidos , Asfixia Neonatal/sangre , Asfixia Neonatal/orina , Biomarcadores/sangre , Biomarcadores/orina , Colina , Femenino , Humanos , Hipoxia Encefálica/metabolismo , Hipoxia Encefálica/fisiopatología , Hipoxia-Isquemia Encefálica/sangre , Hipoxia-Isquemia Encefálica/orina , Embarazo , Índice de Severidad de la Enfermedad , PorcinosRESUMEN
AIM: To investigate whether S100A1B and BB dimers are predictors of early perinatal death in newborns with perinatal asphyxia (PA). METHODS: The study compared 38 full-term newborns with PA [neonatal death n = 11; hypoxic ischaemic encephalopathy (HIE): n = 27] with a control group of 38 healthy infants. Clinical and laboratory parameters were recorded at eight time points and urine collected for S100B assessment. Multivariate analysis was performed in order to analyse the influence of various clinical parameters on the occurrence of neonatal death. RESULTS: A1B and BB in PA nonsurvivor infants were significantly higher (p < 0.001) than in controls at all monitoring time points. BB at first void (cut-off>42 ng/L) was the best predictor of early neonatal death (p < 0.05) of all the clinical and laboratory parameters studied. CONCLUSION: These results suggest that S100s are valuable predictors of adverse outcome in PA infants. It is also suggested that these biomarkers be used in daily clinical practice, due to their low cost and stress, reproducibility and the possibility of longitudinal monitoring.
Asunto(s)
Asfixia Neonatal/mortalidad , Hipoxia-Isquemia Encefálica/mortalidad , Subunidad beta de la Proteína de Unión al Calcio S100/orina , Asfixia Neonatal/diagnóstico , Asfixia Neonatal/terapia , Asfixia Neonatal/orina , Biomarcadores/química , Biomarcadores/orina , Estudios de Casos y Controles , Técnicas de Apoyo para la Decisión , Femenino , Humanos , Hipoxia-Isquemia Encefálica/diagnóstico , Hipoxia-Isquemia Encefálica/terapia , Hipoxia-Isquemia Encefálica/orina , Recién Nacido , Modelos Logísticos , Masculino , Análisis Multivariante , Evaluación de Resultado en la Atención de Salud , Subunidad beta de la Proteína de Unión al Calcio S100/química , Sensibilidad y EspecificidadRESUMEN
BACKGROUND: High-dose recombinant human erythropoietin (rEpo) has first been administered in clinical trials for neuroprotection in very preterm neonates at high risk of brain injury and in (near-) term neonates with hypoxic-ischemic encephalopathy. However, recent trials in adults raised concerns about the safety of high-dose rEpo for neuro- and cardioprotection. OBJECTIVES: To evaluate the putative accumulation or renal leakage of Epo as a function of developmental stage after repetitive early short-term infusion of high-dose rEpo (3 × 3,000 U/kg within 42 h after birth; NCT00413946) for neuroprotection in very preterm infants. METHODS: Epo concentrations were measured using the ELISA technique in the first two consecutive urine specimens after each rEpo infusion. RESULTS: Renal Epo excretion was significantly higher in preterm infants with gestational ages <29 weeks than in more mature infants and reached up to 23% of the administered rEpo within 8 h after each infusion. The urinary Epo concentration did not increase after three repetitive infusions of high-dose rEpo. The ratio of urinary Epo to total protein concentrations was the same in infants with gestational ages <29 weeks and in those with gestational ages ≥29 weeks. CONCLUSIONS: Our data suggest that the higher renal Epo excretion in more immature infants may be attributed to a higher glomerular filtration leakage due to the lower maturation of the kidneys and argue against saturation kinetics after multiple doses of 3,000 U/kg rEpo. This information should be considered in future trials on the use of rEpo for neuroprotection in neonates.
Asunto(s)
Anemia Neonatal/prevención & control , Citoprotección/efectos de los fármacos , Eritropoyetina/administración & dosificación , Eritropoyetina/orina , Recien Nacido Prematuro , Neuronas/efectos de los fármacos , Anemia Neonatal/metabolismo , Anemia Neonatal/orina , Relación Dosis-Respuesta a Droga , Método Doble Ciego , Eritropoyetina/farmacología , Femenino , Humanos , Hipoxia-Isquemia Encefálica/metabolismo , Hipoxia-Isquemia Encefálica/prevención & control , Hipoxia-Isquemia Encefálica/orina , Recién Nacido , Recien Nacido Prematuro/fisiología , Recien Nacido Prematuro/psicología , Bombas de Infusión , Masculino , Fármacos Neuroprotectores/administración & dosificación , Fármacos Neuroprotectores/farmacocinética , Fármacos Neuroprotectores/farmacología , Fármacos Neuroprotectores/orina , Concentración Osmolar , Placebos , Proteínas Recombinantes/administración & dosificación , Proteínas Recombinantes/farmacocinética , Proteínas Recombinantes/farmacología , Proteínas Recombinantes/orina , Factores de TiempoRESUMEN
BACKGROUND: Early identification and prevention of hypoxic-ischemic encephalopathy (HIE) in newborns may reduce neonatal mortality and neurological dysfunction. OBJECTIVE: To analyze the diagnostic and prognostic values of urinary S100B level and lactate/creatinine ratio in newborns with HIE. METHODS: Seventy-eight full-term newborns with HIE and 25 normal newborns were enrolled. The Neonatal Behavioral Neurological Assessment (NBNA) and Developmental Screening Test were scored. The concentration of urinary S100B protein was determined using the S100B enzyme-linked immunosorbent assay and the levels of urinary lactate and creatinine were measured with the enzyme colorimetric method. RESULTS: Urinary S100B level on days 1-3 after birth and lactate/creatinine ratio on day 1 were significantly higher in newborns with HIE than those in the control group. Both indexes were positively correlated with the clinical grading of HIE. A cutoff value for the S100B level of 0.47 microg/l on day 3 after birth had a sensitivity of 90% and specificity of 92% for prediction of HIE. A lactate/creatinine ratio of more than 0.55 on day 1 showed the highest sensitivity (92%) and specificity (90%). A combination of both indexes improved the sensitivity and specificity to 99 and 97%, respectively. A negative correlation of both lactate/creatinine ratio on day 1 and S100B level on days 1-3 after birth with the NBNA score was identified on days 3, 7 and 14 after birth. The Developmental Screening Test score of 36 newborns with HIE within 6 months after birth showed that 65% of infants with moderate and high HIE had an abnormal developmental quotient. CONCLUSION: These data suggest that early measurement of both S100B level and lactate/creatinine ratio in the urine of newborns with HIE is a practical convenient and sensitive way to improve diagnosis on the third day of life and prognostic prediction of HIE.
Asunto(s)
Asfixia Neonatal/diagnóstico , Creatinina/orina , Discapacidades del Desarrollo/diagnóstico , Hipoxia-Isquemia Encefálica/diagnóstico , Ácido Láctico/orina , Factores de Crecimiento Nervioso/orina , Proteínas S100/orina , Asfixia Neonatal/complicaciones , Asfixia Neonatal/orina , Biomarcadores , Desarrollo Infantil , Discapacidades del Desarrollo/etiología , Discapacidades del Desarrollo/orina , Humanos , Hipoxia-Isquemia Encefálica/etiología , Hipoxia-Isquemia Encefálica/orina , Conducta del Lactante , Recién Nacido , Pronóstico , Subunidad beta de la Proteína de Unión al Calcio S100RESUMEN
Urinary S100A1B and S100BB were measured to detect cases at risk of hypoxic-ischemic encephalopathy (HIE) in asphyxiated newborns. We recruited 42 asphyxiated infants and 63 healthy term neonates. S100A1B and S100BB were measured at first urination (time 0) and at 4 (time 1), 8 (time 2), 12 (time 3), 16 (time 4), 20 (time 5), 24 (time 6), 72 (time 7) hours after birth. 20 infants had no/mild HIE with good prognosis (Group A) and 22 had moderate/severe HIE with a greater risk of neurological handicap (Group B). Urine S100A1B and S100BB levels were significantly (P less than 0.0.01, for all) higher at all monitoring time-points in Group B than Group A and controls, but not between Group A and controls. Both S100A1B and S100BB have great sensitivity and specificity for HIE since their first measurement. In conclusion, S100A1B and S100BB are increased in urine collected from asphyxiated newborns who will develop HIE since first urination, and their measurement may be useful to early predict HIE when monitoring procedures are still of no avail.
Asunto(s)
Asfixia Neonatal/complicaciones , Biomarcadores/orina , Hipoxia-Isquemia Encefálica/diagnóstico , Hipoxia-Isquemia Encefálica/orina , Factores de Crecimiento Nervioso/orina , Proteínas S100/orina , Análisis de Varianza , Cerebro/diagnóstico por imagen , Humanos , Hipoxia-Isquemia Encefálica/etiología , Recién Nacido , Subunidad beta de la Proteína de Unión al Calcio S100 , Sensibilidad y Especificidad , Estadísticas no Paramétricas , Factores de Tiempo , UltrasonografíaRESUMEN
OBJECTIVE: To assess the association between urinary lactate to creatinine ratio (ULCR) and neurodevelopmental outcome in term infants with hypoxic ischemic encephalopathy and examine the effect of hypothermia on the change in ULCR. STUDY DESIGN: Spot urine samples were collected in 58 term infants (28 hypothermia, 30 control subjects) with hypoxic ischemic encephalopathy. Urinary lactate and creatinine were measured by using (1)H nuclear magnetic resonance spectroscopy and expressed as ULCR. Survivors were examined at 18 months of age. RESULTS: The ULCR was significantly higher in infants who died or had moderate/severe neurodevelopmental disability. Logistic regression analysis controlling for hypothermia and severity of encephalopathy confirmed the association (adjusted odds ratio, 5.52; 95% CI, 1.36, 22.42; P < .02). Considerable overlap in ULCR was observed between infants with normal/mild disability and those who died or survived with moderate/severe disability. ULCR fell significantly between 6 and 24 hours and 48 and 72 hours of age for all infants. The magnitude of decline did not differ between hypothermia and control groups. CONCLUSIONS: High ULCR is associated with death or moderate/severe neurodevelopmental disability. Significant overlap in values between the normal/mild and moderate/severe disability groups limits predictive value of this measure. Whole-body hypothermia did not affect the decline in ULCR.
Asunto(s)
Desarrollo Infantil/fisiología , Creatinina/orina , Hipoxia-Isquemia Encefálica/orina , Ácido Láctico/orina , Adulto , Biomarcadores/orina , Femenino , Estudios de Seguimiento , Humanos , Hipotermia Inducida , Hipoxia-Isquemia Encefálica/fisiopatología , Hipoxia-Isquemia Encefálica/terapia , Lactante , Recién Nacido , Espectroscopía de Resonancia Magnética , Masculino , Embarazo , Pronóstico , Índice de Severidad de la Enfermedad , Factores de TiempoRESUMEN
BACKGROUND: Hypoxic ischemic encephalopathy (HIE) is a major cause of permanent neurological disabilities in full-term newborns. We measured activin A in urine collected immediately after birth in asphyxiated full-term newborns, and assessed the ability of the measurements to predict the occurrence of perinatal encephalopathy. METHODS: We studied 30 infants with perinatal asphyxia and 30 healthy term neonates at the same gestational age. We recorded routine laboratory variables, cranial assessments by standard cerebral ultrasound, and the presence or absence of neurological abnormalities during the first 7 days after birth. Urinary activin A concentrations were measured at first urination and 12, 24, 48, and 72 h after birth. RESULTS: Asphyxiated infants were subdivided as follows: group A (n = 18): no or mild HIE with good prognosis and group B (n = 12): moderate or severe HIE with a greater risk of neurological handicap. Activin A concentrations in urine collected at birth (median collection time at first urination <2 h) and at 12, 24, 48, and 72 h from birth were significantly (P <0.0001) higher in asphyxiated newborns with moderate or severe HIE (Group B) than in those with absent of mild HIE (group A) and controls. Concentrations did not differ between group A and controls. Activin A concentrations were >0.08 mug/L at first urination in 10 of 12 patients with moderate or severe HIE but in none of 18 patients with no or mild HIE. CONCLUSIONS: Activin A measurements in urine soon after birth may be a promising tool to identify which asphyxiated infants are at risk of neurological sequelae.
Asunto(s)
Activinas/orina , Asfixia Neonatal/diagnóstico , Hipoxia-Isquemia Encefálica/diagnóstico , Asfixia Neonatal/complicaciones , Asfixia Neonatal/orina , Biomarcadores/orina , Humanos , Hipoxia-Isquemia Encefálica/etiología , Hipoxia-Isquemia Encefálica/orina , Recién Nacido , Valor Predictivo de las PruebasRESUMEN
OBJECTIVE: To investigate the value of urinary S100B protein and lactate/creatinine ratio determination in early identification of neonatal hypoxic-ischemic encephalopathy (HIE). METHODS: The levels of urinary S100B protein and urinary lactate/creatinine ratio were detected in 58 full-term newborn infants with HIE on the first, second and third day after birth. The severity of clinical manifestations, including the degree of encephalopathy, was assessed within 7 days after birth. Twenty five normal neonates were enrolled into the control groups. RESULTS: (1) The urinary S100B level of HIE neonates was significantly higher in samples collected throughout the monitoring period than those of the normal control groups (all P < 0.001). The urinary lactate/creatinine ratio of the HIE neonates was also significantly higher than that of normal control groups within the first day (P < 0.001). (2) A significantly positive correlation was found between the level of urinary S100B protein within three days and the urinary lactate/creatinine ratio within the first day and between the level of urinary S100B protein within three days and clinical degree (P < 0.05). (3) When S100B concentration was 0.47 microg/L and urinary lactate/creatinine ratio was 0.55, the sensitivity and specificity of detecting the third day urinary S100B alone, were respectively 90.4%, 91.9%. Detecting it associated with the first day urinary lactate/creatinine ratio could increase the sensitivity and specificity (respectively 98.8% and 97.4%) for predicting development of HIE. CONCLUSION: On the basis of clinical manifestations of asphyxic neonatals, detecting the level of urinary S100B within three days and the first day urinary lactate/creatinine ratio may be of important value in early diagnosis and grading of HIE.
Asunto(s)
Creatinina/orina , Hipoxia-Isquemia Encefálica/diagnóstico , Hipoxia-Isquemia Encefálica/orina , Ácido Láctico/orina , Factores de Crecimiento Nervioso/orina , Proteínas S100/orina , Puntaje de Apgar , Asfixia Neonatal/complicaciones , Diagnóstico Precoz , Femenino , Humanos , Hipoxia-Isquemia Encefálica/etiología , Recién Nacido , Masculino , Subunidad beta de la Proteína de Unión al Calcio S100 , Tomografía Computarizada por Rayos XAsunto(s)
Dinoprost/análogos & derivados , Hipoxia-Isquemia Encefálica/diagnóstico , Hipoxia-Isquemia Encefálica/orina , Asfixia Neonatal/complicaciones , Biomarcadores/orina , Dinoprost/orina , Progresión de la Enfermedad , Femenino , Humanos , Hipoxia-Isquemia Encefálica/etiología , Recién Nacido , Masculino , Valor Predictivo de las Pruebas , Índice de Severidad de la Enfermedad , Factores de TiempoAsunto(s)
Biomarcadores/orina , Hipoxia-Isquemia Encefálica/diagnóstico , Factores de Crecimiento Nervioso/orina , Proteínas S100/orina , Asfixia Neonatal/diagnóstico , Autoantígenos/análisis , Autoantígenos/orina , Biomarcadores/análisis , Daño Encefálico Crónico/etiología , Humanos , Hipoxia-Isquemia Encefálica/orina , Recién Nacido , Factores de Crecimiento Nervioso/análisis , Subunidad beta de la Proteína de Unión al Calcio S100 , Proteínas S100/análisisRESUMEN
BACKGROUND: Perinatal asphyxia is a major cause of mortality and morbidity. To date there are no reliable methods to detect which infants will develop brain damage after asphyxia insult. We investigated whether measurements of urine levels of S100B in asphyxiated full-term newborns may be a useful tool for early detection of postasphyxia brain damage. METHODS: A prospective study of 38 infants with perinatal asphyxia and 96 control subjects, recruited at 3 tertiary departments of neonatology between April 1, 1999, and July 31, 2001. Routine laboratory variables, neurologic patterns, and urine concentrations of S100B protein were determined at 4 predetermined time points (first urination and 12, 24, and 72 hours after birth). The concentrations of S100B protein in urine were measured using an immunoluminometric assay. The results were correlated with the presence or absence of neurologic abnormalities at age 12 months. RESULTS: S100B protein levels were significantly higher in samples collected at all monitoring times from new-borns with abnormal neurologic findings on follow-up (first urination, 1.92 +/- 0.33 micro g/L; 12 hours, 2.78 +/- 1.71 micro g/L; 24 hours, 4.75 +/- 4.08 micro g/L; 72 hours, 5.93 +/- 1.63 micro g/L) than in samples from those without (first urination, 0.24 +/- 0.06 micro g/L; 12 hours, 0.13 +/- 0.06 micro g/L; 24 hours, 0.21 +/- 0.07 micro g/L; 72 hours, 0.12 +/- 0.04 micro g/L) or from healthy infants (first urination, 0.11 +/- 0.01 micro g/L; 12 hours, 0.12 +/- 0.03 micro g/L; 24 hours, 0.12 +/- 0.02 micro g/L; 72 hours, 0.12 +/- 0.02 micro g/L) (P<.001 for all). An S100B concentration cutoff of 0.28 micro g/L at first urination had a sensitivity of 100% and a specificity of 87.3% for predicting the development of abnormal neurologic findings on follow-up. The sensitivity and specificity of measurements obtained between 12 and 72 hours were up to 100% and 98.2%, respectively. CONCLUSION: Longitudinal S100B protein measurements in urine soon after birth are a useful tool to identify which asphyxiated infants are at risk of long-term neurologic sequelae.